Iradimed Lowers The Top Of Its 2026 Revenue Range To $93.1 Million After A Record Quarter

Third-quarter sales rose 14% to $24.2 million, but gross margin slipped to 76% and inventory grew.

Share
Iradimed Lowers The Top Of Its 2026 Revenue Range To $93.1 Million After A Record Quarter

Iradimed, which makes MRI-compatible IV pumps and patient monitors, cut the ceiling on its full-year revenue outlook to $93.1 million from $96.0 million, even as it posted record third-quarter sales of $24.2 million, the company said Friday. The 10-Q filed the same day shows gross margin down from a year earlier.

A narrower, lower guidance range

Full-year revenue is now guided to $91.6 million to $93.1 million, against $91.0 million to $96.0 million before. Earnings per share on a standard accounting basis is guided to $1.90 to $1.94, replacing $1.90 to $2.05.

For the fourth quarter, the company expects revenue of $25.0 million to $26.5 million and earnings of $0.53 to $0.57 per share. CEO Roger Susi said the quarter would reach a $100.0 million revenue run rate and that record bookings leave the company "well positioned for a strong finish to the year."

Record sales, thinner margin

Third-quarter revenue rose 14% from $21.2 million. Net income reached $6.5 million, or $0.51 per diluted share, against $5.6 million, or $0.43, a year earlier.

Gross margin fell to 76% from 78%, which the 10-Q attributes to initial production inefficiencies on new product manufacturing. Cost of revenue climbed 22% to $5.7 million, outpacing sales growth.

The filing credits the quarter's revenue increase primarily to changes in the sales incentive plan for monitors, infusion pumps and disposables. Pump revenue was $8.7 million, against $8.3 million a year earlier, while monitor revenue rose to $8.0 million from $6.9 million. International sales jumped 45% to $4.5 million.

Inventory builds as cash flow improves

Inventory stood at $13.5 million at September 30, up from $11.6 million at the end of 2025, with raw materials at $11.7 million versus $9.6 million. The company said increased inventory purchases partly offset operating cash flow.

Free cash flow for the first nine months was $20.1 million, against $11.0 million a year earlier, when the company was still spending on its new corporate office and manufacturing facility. Cash totaled $63.3 million.

The company, which sells mainly to hospitals through 28 field sales representatives in the US and independent distributors abroad, declared a $0.20 quarterly dividend payable November 27 to holders of record on November 13.

Fourth-quarter revenue of $25.0 million to $26.5 million is the figure the new full-year range now depends on.

Sources

More on Iradimed

All Iradimed (IRMD) coverage →